1
|
Maria ATJ, Campidelli A, Castilla-Llorente C, Lansiaux P, Marjanovic Z, Pugnet G, Torregrosa-Diaz JM, Terriou L, Algayres JP, Urbain F, Yakoub-Agha I, Farge D. [Vaccination before and after autologous hematopoietic cell transplantation for autoimmune diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (MATHEC-SFGM-TC)]. Bull Cancer 2023; 110:S97-S107. [PMID: 36658011 DOI: 10.1016/j.bulcan.2022.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 11/16/2022] [Accepted: 11/16/2022] [Indexed: 01/18/2023]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 12th workshop on hematopoietic stem cell transplantation clinical practices harmonization procedures on September 2021 in Lille, France. In the absence of specific national or international recommendation, the French working group for autologous stem Cell transplantation in Auto-immune Diseases (MATHEC) proposed guidances for vaccinations of patients undergoing autologous hematopoietic stem cell transplantation for autoimmune disease, including in the context of SARS-Cov-2 pandemic.
Collapse
Affiliation(s)
- Alexandre Thibault Jacques Maria
- Médecine Interne & Immuno-Oncologie (MedI2O), Institute for Regenerative Medicine & Biotherapy (IRMB), Hôpital Saint Eloi, CHU de Montpellier, 80 avenue Augustin Fliche, Montpellier, France; IRMB, Inserm U1183, Hôpital Saint-Eloi, CHU de Montpellier, 34295, Montpellier, France
| | - Arnaud Campidelli
- CHRU Nancy, Service Hématologie Adulte, 54500 Vandoeuvre-lès-Nancy, France
| | - Cristina Castilla-Llorente
- Gustave Roussy Cancer Campus, Département d́Hématologie, 114 rue Edouard Vaillant, 94800 Villejuif, France
| | - Pauline Lansiaux
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France; Université de Paris Cité, Institut de recherche Saint Louis, Recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France
| | - Zora Marjanovic
- Hôpital Saint Antoine (APHP), Service d'Hématologie et Thérapie cellulaire, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Grégory Pugnet
- CHU Rangueil, Service de Médecine Interne et Immunologie Clinique, 1 avenue du Pr Jean Poulhès, 31059 Toulouse Cedex 9, France
| | | | - Louis Terriou
- Hôpital Claude Huriez, CHRU Lille, Service de médecine interne et immunologie clinique, rue Michel Polonovski, 59000 Lille, France
| | - Jean-Pierre Algayres
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France
| | - Fanny Urbain
- Hôpital Bicêtre, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne et Immunologie Clinique, 94275 Le Kremlin-Bicêtre cedex, France; Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
| | | | - Dominique Farge
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France; Université de Paris Cité, Institut de recherche Saint Louis, Recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France; McGill University, Department of Medicine, H3A 1A1, Montreal, Canada.
| |
Collapse
|
2
|
Bertaina A, Abraham A, Bonfim C, Cohen S, Purtill D, Ruggeri A, Weiss D, Wynn R, Boelens JJ, Prockop S. An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. Cytotherapy 2022; 24:385-392. [PMID: 35331394 DOI: 10.1016/j.jcyt.2021.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 09/14/2021] [Accepted: 09/18/2021] [Indexed: 11/19/2022]
Abstract
Allogeneic stem cell transplantation is a potentially curative therapy for some malignant and non-malignant disease. There have been substantial advances since the approaches first introduced in the 1970s, and the development of approaches to transplant with HLA incompatible or alternative donors has improved access to transplant for those without a fully matched donor. However, success is still limited by morbidity and mortality from toxicity and imperfect disease control. Here we review our emerging understanding of how reconstitution of effective immunity after allogeneic transplant can protect from these events and improve outcomes. We provide perspective on milestones of immune reconstitution that are easily measured and modifiable.
Collapse
Affiliation(s)
- Alice Bertaina
- Center for Cancer and Immunology Research, CETI, Children's National Hospital, Washington, District of Columbia, USA
| | - Allistair Abraham
- Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA
| | - Carmem Bonfim
- Pediatric Bone Marrow Transplantation Division, Hospital Pequeno Principe, Curitiba, Brazil
| | - Sandra Cohen
- Université de Montréal and Maisonneuve Rosemont Hospital, Montréal, Québec, Canada
| | - Duncan Purtill
- Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia
| | | | | | - Robert Wynn
- Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
| | - Jaap Jan Boelens
- Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, and Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA
| | - Susan Prockop
- Stem Cell Transplant Program, Division of Hematology/Oncology Boston Children's Hospital and Department of Pediatric Oncology, Dana Farber Cancer Institute.
| |
Collapse
|
3
|
Pagano L, Salmanton-García J, Marchesi F, Lopez-Garcia A, Lamure S, Itri F, Gomes da Silva M, Dragonetti G, Falces-Romero I, van Doesum J, Sili U, Labrador J, Calbacho M, Bilgin Y, Weinbergerová B, Serrano Gomez LM, Ribera JM, Malak S, Loureiro-Amigo J, Glenthøj A, Cordoba R, Nunes Rodrigues R, Gonzalez-Lopez TJ, Karlsson LK, Jimenez MJ, Hernández-Rivas JÁ, Jaksic O, Racil Z, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely O. COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA. Blood 2021:blood. [PMID: 34748627 DOI: 10.1182/blood.2021014124] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Accepted: 10/13/2021] [Indexed: 11/20/2022] Open
|
4
|
Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, Tacconelli E. A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. Infect Dis Ther 2021; 10:637-661. [PMID: 33687662 PMCID: PMC7941364 DOI: 10.1007/s40121-021-00404-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 01/20/2021] [Indexed: 12/29/2022] Open
Abstract
Vaccine-preventable diseases and their related complications are associated with increased morbidity and mortality in patients with altered immunocompetence. Optimised immunisation in this patient population is challenging because of limited data from vaccine trials, suboptimal vaccine efficacy and safety concerns. Reliable efficacy data are lacking among patients with altered immunocompetence, and existing recommendations are mainly based on expert consensus and may vary geographically. Inactivated vaccines can be generally used without risks in this group, but their efficacy may be reduced, and immunisation schedules vary according to local guidelines, age, and type and stage of the underlying disease. Live vaccines, if indicated, should be administered with care because of the risk of vaccine-associated disease. We have reviewed the current evidence on vaccination principles and recommendations in adult patients with secondary immunodeficiencies, including asplenia, HIV infection, stem cell and solid organ transplant, haematological malignancies, inflammatory bowel disease and other chronic disorders.
Collapse
Affiliation(s)
- Elda Righi
- Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
- Infectious Diseases, Verona University Hospital, Verona, Italy.
| | - Tolinda Gallo
- Public Health Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Anna Maria Azzini
- Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- Infectious Diseases, Verona University Hospital, Verona, Italy
| | | | - Maddalena Cordioli
- Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- Infectious Diseases, Verona University Hospital, Verona, Italy
| | - Mara Merighi
- Infectious Diseases, Verona University Hospital, Verona, Italy
| | - Evelina Tacconelli
- Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- Infectious Diseases, Verona University Hospital, Verona, Italy
| |
Collapse
|
5
|
Chevallier P, Coste-Burel M, Le Bourgeois A, Peterlin P, Garnier A, Béné MC, Imbert BM, Drumel T, Le Gouill S, Moreau P, Mahe B, Dubruille V, Blin N, Lok A, Touzeau C, Gastinne T, Jullien M, Vanthygem S, Guillaume T. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. ACTA ACUST UNITED AC 2021; 2:520-524. [PMID: 34226903 PMCID: PMC8242867 DOI: 10.1002/jha2.242] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 05/18/2021] [Accepted: 05/18/2021] [Indexed: 12/28/2022]
Abstract
This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer‐BioNTech) in 112 Allo‐HSCT patients. Antibody response to SARS‐CoV‐2 spike protein receptor‐binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non‐randomized control arm of 26 healthy controls. This study shows that a first dose of SARS‐CoV‐2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 109/L) and immunosuppressive treatment or chemotherapy at the time of vaccination.
Collapse
Affiliation(s)
- Patrice Chevallier
- Department of Hematology Nantes University Hospital Nantes France.,INSERM UMR1232 CRCINA IRS-UN University of Nantes Nantes France
| | | | | | - Pierre Peterlin
- Department of Hematology Nantes University Hospital Nantes France
| | - Alice Garnier
- Department of Hematology Nantes University Hospital Nantes France
| | - Marie C Béné
- INSERM UMR1232 CRCINA IRS-UN University of Nantes Nantes France.,Department of Hematology Biology Nantes University Hospital Nantes France
| | | | - Thomas Drumel
- Department of Virology Nantes University Hospital Nantes France
| | - Steven Le Gouill
- Department of Hematology Nantes University Hospital Nantes France
| | - Philippe Moreau
- Department of Hematology Nantes University Hospital Nantes France
| | - Beatrice Mahe
- Department of Hematology Nantes University Hospital Nantes France
| | | | - Nicolas Blin
- Department of Hematology Nantes University Hospital Nantes France
| | - Anne Lok
- Department of Hematology Nantes University Hospital Nantes France
| | - Cyrille Touzeau
- Department of Hematology Nantes University Hospital Nantes France
| | - Thomas Gastinne
- Department of Hematology Nantes University Hospital Nantes France
| | - Maxime Jullien
- Department of Hematology Nantes University Hospital Nantes France
| | - Sophie Vanthygem
- Department of Hematology Nantes University Hospital Nantes France
| | - Thierry Guillaume
- Department of Hematology Nantes University Hospital Nantes France.,INSERM UMR1232 CRCINA IRS-UN University of Nantes Nantes France
| |
Collapse
|
6
|
Abstract
Following primary infection, herpesviruses establish latency in infected individuals in the host cells and may reactivate upon external stimuli and during periods of immunosuppression. The objective of this paper was to the present current strategies on preventive and therapeutic management of infections with herpesviruses in recipients of hematopoietic cell transplantation. Strategies of antiviral management include prophylaxis, pre-emptive treatment and targeted treatment. Empirical therapy is not used in antiviral strategies. Prophylaxis can be done at universal (preventive strategy) and specific level. Universal prophylaxis includes non-pharmacologic methods of prevention of infection or reactivation. Risk-adapted specific prophylaxis includes use of specific antivirals or cellular therapy or other specific methods in order to prevent specific infection, in high-risk groups. Pre-emptive therapy means use of therapeutic approaches in asymptomatic infection, detected by a screening assay. Targeted therapy is used in established specific viral end-organ infections. The following sections of the paper refer to prophylaxis and treatment strategies, respectively, against CMV, EBV, HSV, VZV, HHV-6, HHV-7, and HHV-8 after allogeneic hematopoietic cell transplantation.
Collapse
|
7
|
von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, Hirsch HH. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia 2020; 34:1487-1494. [PMID: 32358568 PMCID: PMC7194246 DOI: 10.1038/s41375-020-0832-y] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 03/30/2020] [Accepted: 04/03/2020] [Indexed: 01/03/2023]
Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
Collapse
Affiliation(s)
- Marie von Lilienfeld-Toal
- Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
- Leibniz-Institut für Infektionsbiologie und Naturstoff Forschung, Hans-Knöll Institut, Jena, Germany.
| | - Jörg Janne Vehreschild
- Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany
- Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
| | - Oliver Cornely
- Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany
- EHA Infectious Diseases Scientific Working Group, Cologne, Germany
| | - Livio Pagano
- Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy
| | - Francesca Compagno
- Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Hans H Hirsch
- Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
- Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland
- Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|